JCB, Volume 22, Number 1, 2016 Commentary Vol.22 No. 1 (2016) An Impediment to Personalized Medicine Commercialization is the Lack of Understanding of the Value of the Testing Anthony Johnson Over the past 20 years there have been tremendous advancements in technology in areas such as imaging, medicinal chemistry, data integration, the digitization of medical records, computing p Article Vol.22 No. 1 (2016) Biopharmaceutical Startup’s Need of a Regulatory Strategy Julia Schueler Human drug development and approval is a risky process. To assess the importance of the regulatory part, especially for startup’s or not yet established companies, we gathered some Article Vol.22 No. 1 (2016) Marketing authorization of medical devices in China Weifan Zhang Medical device regulations across the globe have significant variations. The Chinese medical device market, like China’s economy, is developing rapidly. This article reviews the medic Article Vol.22 No. 1 (2016) VC-backed Biotechnology Firms: What is Entrepreneurs’ Return? Demetris Iacovides Valuation is a highly significant process used extensively not only by start-ups seeking Venture Capital (VC) funding but also by large, established companies that are in need to set a price Article Vol.22 No. 1 (2016) Encouraging Innovation in Preventive Health Technology: A Spotlight on Women's Health Elizabeth Ann McCaman Encouraging technology innovation, specifically preventive health technology, can use the intellectual property regime to the public health's benefit.  Patents today are currently concent Article Vol.22 No. 1 (2016) Intellectual Property Protection for Biologics: Why the Trans-Pacific Partnership (TPP) Trade Agreement Fails to Deliver Kristina M Lybecker Biopharmaceutical research and development is overwhelmingly focused in the U.S. becasue here it is incentivized and encouraged through a robust intellectual property rights protection envir Article Vol.22 No. 1 (2016) Using a Rasch Model to Rank Big Pharmaceutical Firms by Financial Performance Thani Jambulingam We explore a Rasch approach to ranking the top 15 firms in the pharmaceutical industry by their overall financial performance. Using an initial set of ratios spanning multiple dimensi Conference Report Vol.22 No. 1 (2016) Moving from preclinical research to development Vasu Pestonjamasp
